Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AGO Study Group
Patients with epithelial ovarian, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. Many patients respond to additional cytotoxic treatment with partial or complete responses, yet approximately 100% of these patients will ultimately progress. Novel consolidation strategies following treatment for recurrent disease are needed and an immunologic approach is an attractive option.
Age
0–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with epithelial carcinoma arising in the ovary, fallopian tube or peritoneum, stages I-IV. These patients must have received initial surgery and chemotherapy with at least one platinum based chemotherapy regimen.
Patients must have relapsed and now have completed chemotherapy for recurrent disease within the last 6 weeks.
Eligible patients may have asymptomatic residual measurable disease on CT scan, and/or may have an elevated CA-125, or may be in complete clinical remission.
Patients must have adequate hematologic, renal and hepatic functions.
You may not be if
Patients with any other active malignancy concomitantly
Patients within 3 weeks of prior cytotoxic or investigational chemotherapy
Patients within 4 weeks of prior radiotherapy
Patients within 6 weeks of prior immunotherapy
Patients who have received any prior anti-cancer vaccine